CMX521

CMX521
Legal status
Legal status	US: Investigational drug;
Identifiers
	IUPAC name 4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methylpyrrolo[2,3-d]pyrimidine-5-carboxamide;
CAS Number	2077178-99-3 ;
PubChem CID	126520436;
ChemSpider	95601723;
UNII	76US2C2X3F;
Chemical and physical data
Formula	C13H17N5O5
Molar mass	323.309 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC(=C2C(=CN(C2=N1)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)C(=O)N)N;
	InChI InChI=1S/C13H17N5O5/c1-4-16-10(14)7-5(11(15)22)2-18(12(7)17-4)13-9(21)8(20)6(3-19)23-13/h2,6,8-9,13,19-21H,3H2,1H3,(H2,15,22)(H2,14,16,17)/t6-,8-,9-,13-/m1/s1; Key:PMQFVTNOZQVIOK-HTVVRFAVSA-N;

CMX521 is an antiviral drug discovered by Chimerix, which was developed for the treatment of norovirus, though it also shows efficacy against related viral diarrheas such as rotavirus and some sapoviruses, astroviruses and adenoviruses. It is a nucleoside analogue which acts as an inhibitor of viral RNA-dependant RNA polymerase.^[1]^[2]^[3]